Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.

[1]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[2]  Masatoshi Kudo,et al.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[3]  E. Amir,et al.  Evolution of Randomized Trials in Advanced/Metastatic Soft Tissue Sarcoma: End Point Selection, Surrogacy, and Quality of Reporting. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Wolchok,et al.  Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  V. Prasad,et al.  Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs. , 2016, Mayo Clinic proceedings.

[6]  Fengmin Zhao.  Surrogate End Points and Their Validation in Oncology Clinical Trials. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma , 2015, BMC Research Notes.

[8]  A. Russo,et al.  Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis , 2015, PloS one.

[9]  Joon-Oh Park,et al.  Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. , 2015, The Lancet. Oncology.

[10]  Myeong-Jin Kim,et al.  Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. , 2015, Journal of hepatology.

[11]  Sean Khozin,et al.  Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[13]  Katherine Karakasis,et al.  Outcomes and endpoints in trials of cancer treatment: the past, present, and future. , 2015, The Lancet. Oncology.

[14]  M. Peck‐Radosavljevic.  50 years of EASL--from a European to a global perspective. , 2015, Journal of hepatology.

[15]  F. Cappuzzo,et al.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.

[16]  M. Kudo,et al.  RESORCE: An ongoing randomized, double-blind, phase III trial of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing on sorafenib (SOR). , 2014 .

[17]  Mohamed Bouattour,et al.  Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib. , 2014, The oncologist.

[18]  J. Llovet,et al.  Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design , 2014, Clinical Cancer Research.

[19]  I. Tannock,et al.  Critical evaluation of disease stabilization as a measure of activity of systemic therapy: lessons from trials with arms in which patients do not receive active treatment. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Kudo,et al.  Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  L. Jeng,et al.  Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  T. Seo,et al.  Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. , 2013, Journal of hepatology.

[23]  Zhengjia Chen,et al.  mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  O. Yokosuka,et al.  Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma , 2013, Hepatology International.

[25]  D. Sahani,et al.  Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma. , 2013, Journal of hepatology.

[26]  K. Chayama,et al.  Evaluation of the mRECIST and α-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib , 2012, Oncology.

[27]  Y. Rolland,et al.  Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma , 2012, Cancer.

[28]  Tim Meyer,et al.  EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. , 2011, Journal of hepatology.

[29]  A. Benson,et al.  Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. , 2011, Gastroenterology.

[30]  C. Claussen,et al.  Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. , 2011, Academic radiology.

[31]  Riccardo Lencioni,et al.  Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.

[32]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[33]  Riccardo Lencioni,et al.  Design and endpoints of clinical trials in hepatocellular carcinoma. , 2008, Journal of the National Cancer Institute.

[34]  I. Tannock,et al.  Reflections on medical oncology: 25 years of clinical trials--where have we come and where are we going? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  L. Siu,et al.  Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Haesun Choi,et al.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  J. Bruix,et al.  Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma , 2004, Hepatology.

[38]  Richard Pazdur,et al.  End points and United States Food and Drug Administration approval of oncology drugs. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Ramon Planas,et al.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial , 2002, The Lancet.

[40]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[41]  G. Molenberghs,et al.  Criteria for the validation of surrogate endpoints in randomized experiments. , 1998, Biometrics.

[42]  J R Anderson,et al.  Analysis of survival by tumor response. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.